All Type of News
KPA to hold a national pharmacist conference in Nov.
Amid the upcoming presidential election event the Korea Pharmaceutical Association (KPA) has prepared a plan to have a national conference of all member pharmacists in Nov. in an attempt to maximize the political musc...
GLP evaluation committee to be set up
The government will shorten the period of designating new institutes for good laboratory practice (GLP) from the current three months and to two month and speed up its GLP-related handling procedures.
The Korea Foo...
Damages caused by KORUS FTA in drug industry addressed to political circles.The drug industry strongly claimed that the implementation of government's positive list system and cGMP should be postponed and the industry needed the government's tax privile...
|
Korea should support research-oriented generic makers with incentivesThe government needs to improve overall pricing conditions for domestic generic makers with an innovative drug technology, said a local professor on April 19.
In a recent sym...
|
Foreign-invested pharmaceutical firms increase market share
With foreign drug makers taking a bigger share of the domestic prescription market and mid-tier companies facing restructuring, Korea's pharmaceutical industry is expecting major changes.
According to Mirae Asset ...
Health insurance to cover more medical fees for serious illnesses
National health insurance will cover the additional medical fees in patients who pay more than two million won for six months from three million won, due to government measures expanding national health insurance cove...
Once-a-month drug for osteoporosis soon to launch.
A tensional atmosphere seems to surface to the 130 billion won worth of anti-osteoporosis drug markets by upcoming market launch of a new once-a-month administering drug, perhaps within this week at the earlist.
C...
Phase II study for Zydena successfully completed in U. S.
The phase II clinical study of Zydena in the United States was successfully completed and may give a good chance for its FDA approval in due course.
Dong-A PharmTec, a subsidiary of Dong-A playing a major role for ...
Hanmi wins gemicitabine patent
Hanmi Pharm announced on April it acquired a Korean patent related to a core technology of producing gemcitabine intermediate, entitled 1--halo-2,2-difluoro-2-deoxy-D-ribofuranose derivative and its manufacturing meth...
Government urged to put brake on new product licenses
Critics say the government should put a brake on drug makers' attempts to obtain a number of product licenses for their profits, as a total of 67,176 items were approved as of March 2007, according to a report rel...
